Sarcopenia is an Independent Predictor of Complications Following Pancreatectomy for Adenocarcinoma

Overview

Journal J Surg Oncol

Specialties General Surgery
Oncology

Date 2015 Jan 6

PMID 25556324

Citations 107

Authors

Savita Joglekar

Aeen Asghar

Sarah L Mott

Benjamin E Johnson

Anna M Button

Eve Clark

James J Mezhir

Affiliations

Soon will be listed here.

Abstract

Background And Objectives: Sarcopenia, which is subclinical loss of skeletal muscle mass, is commonly observed in patients with malignancy. The objective of this study is to determine the correlation between sarcopenia and operative complications following pancreatectomy for cancer.

Methods: A retrospective review of a pancreatectomy database was performed. The Hounsfield Unit Average Calculation (HUAC) of the psoas muscle, a marker of muscle density and fatty infiltration, was measured from preoperative CT scans. Complications were graded and multivariate logistic regression analysis was performed.

Results: One hundred eighteen patients met criteria for analysis; the overall morbidity rate was 78.8% (n = 93). There were 31 (26.3%) patients who met criteria for sarcopenia using the HUAC. When analyzed as a continuous variable, sarcopenia was an independent predictor of major grade III complications, length of stay, intensive care unit admission, delayed gastric emptying, and infectious, gastrointestinal, pulmonary, and cardiac complications.

Conclusions: These data suggest that sarcopenia as measured with the HUAC, a value that can be obtained from a preoperative CT scan, is a significant independent predictor of surgical outcome and can be used to improve patient selection and informed consent prior to pancreatectomy in patients with cancer.

Citing Articles

Low skeletal muscle mass as a proxy marker of sarcopenia is a risk factor for major complications in older patients undergoing curative colon resections for colon cancer.

Tirnova I, Gasimova M, Akay H, Sariturk C, Guven Mert A, Yenidunya O Front Med (Lausanne). 2025; 11():1464978.

PMID: 39850105 PMC: 11754278. DOI: 10.3389/fmed.2024.1464978.

Low L3 skeletal muscle index and endometrial cancer: a statistic pooling analysis.

Aru N, Yang C, Chen Y, Liu J BMC Cancer. 2025; 25(1):43.

PMID: 39780132 PMC: 11716173. DOI: 10.1186/s12885-025-13430-7.

High Prevalence of Sarcopenia in Patients with Newly Diagnosed Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs), but No Association with the Risk of Surgical Complications.

Clement D, van Leerdam M, Tesselaar M, Srinivasan P, Menon K, Kuhlmann K Nutrients. 2024; 16(22).

PMID: 39599579 PMC: 11597585. DOI: 10.3390/nu16223790.

MRI-Based Phenotyping for Osteosarcopenic Adiposity in Subjects from a Population-Based Cohort.

Maurer E, Rospleszcz S, Rathmann W, Thorand B, Peters A, Schlett C Geriatrics (Basel). 2024; 9(6).

PMID: 39584951 PMC: 11587111. DOI: 10.3390/geriatrics9060150.

Skeletal Muscle Index Changes on Locoregional Treatment Application After FOLFIRINOX and Survival in Pancreatic Cancer.

Min J, Yu J, Kim S, Kim Y, Kim K, Park H J Cachexia Sarcopenia Muscle. 2024; 16(1):e16343.

PMID: 39578950 PMC: 11670158. DOI: 10.1002/jcsm.13643.

References

Lu C, Yang K, Chang H, Lee L, Chen C, Huang K . Sarcopenic obesity is closely associated with metabolic syndrome. Obes Res Clin Pract. 2013; 7(4):e301-7. DOI: 10.1016/j.orcp.2012.02.003. View

Kim T, Choi K . Sarcopenia: definition, epidemiology, and pathophysiology. J Bone Metab. 2014; 20(1):1-10. PMC: 3780834. DOI: 10.11005/jbm.2013.20.1.1. View

Christians K, Tsai S, Mahmoud A, Ritch P, Thomas J, Wiebe L . Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm?. Oncologist. 2014; 19(3):266-74. PMC: 3958454. DOI: 10.1634/theoncologist.2013-0273. View

Valle J, Palmer D, Jackson R, Cox T, Neoptolemos J, Ghaneh P . Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. J Clin Oncol. 2014; 32(6):504-12. DOI: 10.1200/JCO.2013.50.7657. View

Van Buren 2nd G, Bloomston M, Hughes S, Winter J, Behrman S, Zyromski N . A randomized prospective multicenter trial of pancreaticoduodenectomy with and without routine intraperitoneal drainage. Ann Surg. 2013; 259(4):605-12. DOI: 10.1097/SLA.0000000000000460. View

van der Gaag N, Harmsen K, Eshuis W, Busch O, van Gulik T, Gouma D . Pancreatoduodenectomy associated complications influence cancer recurrence and time interval to death. Eur J Surg Oncol. 2014; 40(5):551-558. DOI: 10.1016/j.ejso.2013.12.012. View

Merkow R, Bilimoria K, Tomlinson J, Paruch J, Fleming J, Talamonti M . Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer. Ann Surg. 2013; 260(2):372-7. DOI: 10.1097/SLA.0000000000000378. View

House M, Fong Y, Arnaoutakis D, Sharma R, Winston C, Protic M . Preoperative predictors for complications after pancreaticoduodenectomy: impact of BMI and body fat distribution. J Gastrointest Surg. 2007; 12(2):270-8. DOI: 10.1007/s11605-007-0421-7. View

Lee G, Fong Z, Ferrone C, Thayer S, Warshaw A, Lillemoe K . High performing whipple patients: factors associated with short length of stay after open pancreaticoduodenectomy. J Gastrointest Surg. 2014; 18(10):1760-9. DOI: 10.1007/s11605-014-2604-3. View

10.

Antoun S, Birdsell L, Sawyer M, Venner P, Escudier B, Baracos V . Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study. J Clin Oncol. 2010; 28(6):1054-60. DOI: 10.1200/JCO.2009.24.9730. View

11.

Von Hoff D, Ervin T, Arena F, Chiorean E, Infante J, Moore M . Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013; 369(18):1691-703. PMC: 4631139. DOI: 10.1056/NEJMoa1304369. View

12.

Cruz-Jentoft A, Baeyens J, Bauer J, Boirie Y, Cederholm T, Landi F . Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010; 39(4):412-23. PMC: 2886201. DOI: 10.1093/ageing/afq034. View

13.

Kim S, Han H, Jung H, Kim K, Hwang D, Kang S . Multidimensional frailty score for the prediction of postoperative mortality risk. JAMA Surg. 2014; 149(7):633-40. DOI: 10.1001/jamasurg.2014.241. View

14.

Petermann D, Demartines N, Schafer M . Severe postoperative complications adversely affect long-term survival after R1 resection for pancreatic head adenocarcinoma. World J Surg. 2013; 37(8):1901-8. DOI: 10.1007/s00268-013-2023-8. View

15.

Mezhir J . Management of complications following pancreatic resection: an evidence-based approach. J Surg Oncol. 2012; 107(1):58-66. DOI: 10.1002/jso.23139. View

16.

Vollmer Jr C, Sanchez N, Gondek S, McAuliffe J, Kent T, Christein J . A root-cause analysis of mortality following major pancreatectomy. J Gastrointest Surg. 2011; 16(1):89-102. DOI: 10.1007/s11605-011-1753-x. View

17.

Peng P, Hyder O, Firoozmand A, Kneuertz P, Schulick R, Huang D . Impact of sarcopenia on outcomes following resection of pancreatic adenocarcinoma. J Gastrointest Surg. 2012; 16(8):1478-86. PMC: 3578313. DOI: 10.1007/s11605-012-1923-5. View

18.

Shaib Y, Davila J, Naumann C, El-Serag H . The impact of curative intent surgery on the survival of pancreatic cancer patients: a U.S. Population-based study. Am J Gastroenterol. 2007; 102(7):1377-82. DOI: 10.1111/j.1572-0241.2007.01202.x. View

19.

Reisinger K, van Vugt J, Tegels J, Snijders C, Hulsewe K, Hoofwijk A . Functional compromise reflected by sarcopenia, frailty, and nutritional depletion predicts adverse postoperative outcome after colorectal cancer surgery. Ann Surg. 2014; 261(2):345-52. DOI: 10.1097/SLA.0000000000000628. View

20.

Peng P, Van Vledder M, Tsai S, Jong M, Makary M, Ng J . Sarcopenia negatively impacts short-term outcomes in patients undergoing hepatic resection for colorectal liver metastasis. HPB (Oxford). 2011; 13(7):439-46. PMC: 3133709. DOI: 10.1111/j.1477-2574.2011.00301.x. View